Get the Stockscreener App
0.8151
0.32%
-0.0026
After Hours:
.81
-0.0051
-0.63%
Talphera Inc stock is traded at $0.8151, with a volume of 43,478.
It is down -0.32% in the last 24 hours and up +3.69% over the past month.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
See More
Previous Close:
$0.8177
Open:
$0.8051
24h Volume:
43,478
Relative Volume:
0.23
Market Cap:
$42.30M
Revenue:
$28,000
Net Income/Loss:
$-14.36M
P/E Ratio:
-2.2455
EPS:
-0.363
Net Cash Flow:
$-11.36M
1W Performance:
-3.88%
1M Performance:
+3.69%
6M Performance:
-39.17%
1Y Performance:
+61.73%
1-Day Range:
$0.8051
$0.8476
1-Week Range:
$0.77
$0.879
52-Week Range:
$0.38
$1.57
Talphera Inc Stock (TLPH) Company Profile
Compare TLPH vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.8151 | 42.44M | 28,000 | -14.36M | -11.36M | -0.363 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-20-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-11-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-05-19 | Resumed | Credit Suisse | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Outperform |
| Apr-24-19 | Resumed | B. Riley FBR | Buy |
| Feb-15-19 | Initiated | Credit Suisse | Outperform |
| Oct-23-18 | Initiated | B. Riley FBR | Buy |
| Oct-13-17 | Downgrade | Jefferies | Buy → Hold |
| Oct-13-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-14-17 | Resumed | Jefferies | Buy |
| Sep-15-16 | Reiterated | ROTH Capital | Buy |
| Aug-05-16 | Downgrade | Stifel | Buy → Hold |
| Oct-30-15 | Upgrade | Jefferies | Hold → Buy |
| Oct-05-15 | Reiterated | ROTH Capital | Buy |
| Sep-02-15 | Initiated | H.C. Wainwright | Buy |
| Jul-10-15 | Resumed | ROTH Capital | Buy |
| May-06-15 | Reiterated | Mizuho | Neutral |
| May-05-15 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-10-15 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-09-15 | Downgrade | Mizuho | Buy → Neutral |
View All
Talphera Inc Stock (TLPH) Latest News
Talphera Inc. (TLPH) Edges Higher as Shares Test Key Resistance at $0.88Bollinger Expansion - Newser
TALPHERA (TLPH) CMO surrenders 4,518 shares to cover RSU tax - Stock Titan
Talphera Earnings Call Highlights NEPHRO Trial Momentum - The Globe and Mail
TLPH Stock Price, Quote & Chart | TALPHERA INC (NASDAQ:TLPH) - ChartMill
WestPark Capital initiates coverage of Talphera (TLPH) with buy recommendation - MSN
Talphera (TLPH) Amendment: Lytton reports 1.25M shares, 2.5% - Stock Titan
Maxim Group Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Talphera Earnings Call Highlights Trial Momentum, Risks - TipRanks
A. G. P. Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $3.5 - Moomoo
Talphera, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEF - GuruFocus
How to Value Talphera (TLPH) After Q1 2026 Earnings? EPS: Not Di - GuruFocus
Talphera (TLPH) Q1 2026 Earnings Transcript - AOL.com
TLPHNafamostat Study Enrollment Progress and Financial Update - GuruFocus
Talphera targets Niyad PMA filing in 2026 and potential approval in 2027 as NEPHRO enrollment surpasses 50% - MSN
Talphera, Inc Q1 Net Income From Continuing Operations USD -2.556 Million - TradingView
Talphera Q1 2026 Earnings Call Transcript - Benzinga
TLPH: NEPHRO study enrollment exceeds 50%, with top-line data expected in H2 2026 - TradingView
Earnings call transcript: Talphera Inc Q1 2026 highlights cash position and clinical progress - Investing.com UK
Talphera (NASDAQ: TLPH) posts Q1 2026 loss and flags going concern, Nasdaq risk - Stock Titan
Talphera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Talphera: Q1 Earnings Snapshot - KVUE
MSN Money - MSN
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Rosalind-backed holders report 12.9M shares in Talphera (NASDAQ: TLPH) - Stock Titan
Number of shareholders of Talphera, Inc. – NASDAQ:TLPH - TradingView
Talphera Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Is Talphera (TLPH) stock hiding in plain sight? (Smart Money Active) 2026-05-08Reward Analysis - Newser
Talphera (TLPH.US) will release its earnings report after the market closes on May 13. - Moomoo
After the close, Talphera posts Q1 results and holds a 4:30 p.m. ET webcast - Stock Titan
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026 - ChartMill
How Talphera (TLPH) revenue breaks down and what it means (Edges Higher) 2026-05-07Stock News - newser.com
TLPH Stock: WestPark Capital Initiates Buy Rating, May 2026 - Meyka
TLPH Initiated Coverage by WestPark Capital -- Rating Set to Buy - GuruFocus
Talphera (NASDAQ: TLPH) seeks approval for equity and ESPP plan changes - Stock Titan
Talphera files prospectus for resale of up to 30.9M shares by selling stockholders - MSN
AcelRx Pharmaceuticals Q1 2025 Earnings Preview - MSN
Talphera Inc Stock (TLPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):